scholarly journals Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Claudio Cerchione ◽  
Davide Nappi ◽  
Maria Di Perna ◽  
Irene Zacheo ◽  
Anna Emanuele Pareto ◽  
...  

The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies becomes very poor, and the retreatment with previously adopted and effective therapy, although unpredictable, could be an effective option. In this report, we describe the clinical history of a patient, previously treated with 9 lines of therapy, refractory to bortezomib and IMIDs, for whom the retreatment with bendamustine resulted in a stable disease with good quality of life.

2012 ◽  
Vol 53 (9) ◽  
pp. 1714-1721 ◽  
Author(s):  
Adrian Alegre ◽  
Albert Oriol-Rocafiguera ◽  
Jose Garcia-Larana ◽  
Maria-Victoria Mateos ◽  
Anna Sureda ◽  
...  

2019 ◽  
Vol 19 (10) ◽  
pp. e278
Author(s):  
Maria Nassim ◽  
Jonas Nilsson ◽  
Stojan Zavisic ◽  
Mia Malmenäs ◽  
Iain Fotheringham ◽  
...  

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 8233-8233
Author(s):  
L. R. Mileshkin ◽  
A. Roberts ◽  
V. Ganju ◽  
C. Underhill ◽  
J. Catalano ◽  
...  

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5384-5384
Author(s):  
Qingchi Liu ◽  
Huimin Zhang ◽  
Xinwang Feng ◽  
Shujie Wang

Abstract Objective To observe the short-term treatment effect of Huachansu Injection combined with CEMT regimen on patients with relapsed or refractory multiple myeloma and evaluate the quality of life of the patients. Methods The 40 patients of relapsed or refractory multiple myeloma were divided into two groups, 20 patients were in the Chinese and western medicine treatment group, the rest in the control group. The patients in the control group received the CEMT regimen (Carboplatin, Etoposide, Methotrexate, and Thalidomide);and those in the Huachansu group received Huachansu injection on the basis of the CEMT treatment. The Huachansu injection in the 500ml 5% Glucose injection was given by intravenous drop once daily, 10'20ml for each time. The general treatment lasted 3 months and one treatment period was 4 weeks,during each period the patients received the  medicine treatment for 7 days and had a rest for 2 days. The patients in each group were given the syndrome differentiation type of traditional chinese medicinal broth,decoction, once a day. The QLQ-C30 Quality of Life Questionaire(Chinese Version V3.0for clinical use) worked out by EORTC(European Organization For Research And Treatment Of Cancer) was adopted to evaluate and research the patients’ quality of life before and after the treatment. Results 5 cases had complete remission,6 had part remission, 2 had stable and 7 cases had progresss and the total effectiveness reaches 65.0%  in the Huachansu group group. In the control group, 3 cases had complete remission,4 had part remission, 1 had stable and 12 had progress and the total effectiveness reaches 40.0%. The effective rate of Huachansu group is higher than the control group,and the differences was statistically significant(P<0.05).  The quality of life questionaire result also shows that the overall health status and the overall life quality of the patients in both groups have been improved as well as the patients’ physical and mental status. The difference in the patients’ life quality is less obvious in both groups. The 3-month treatment on their role functions and social functions have no outstanding effects after comparation. Conclusion The Huachansu Injection combined with CEMT regimen not only  has excellent effect on on patients with relapsed or refractory multiple myeloma,but also improves the quality of life of patient. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document